Search
MBO7133
go.drugbank.com/drugs/DB04999ExperimentalMB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer. … Higher doses of araC cannot be used to overcome this limitation due to bone marrow toxicity resulting from rapid activation in that tissue.
Perfluorohexyloctane
go.drugbank.com/drugs/DB17823ApprovedInvestigational[A259746] Because it is a completely non-aqueous liquid, microbial growth is not possible; therefore, its drug products do not need to be combined with any preservative. … [A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536]
Estazolam
go.drugbank.com/drugs/DB01215ApprovedIllicitInvestigationalIt has been shown in some cases to be more potent than diazepam or nitrazepam.
Momelotinib
go.drugbank.com/drugs/DB11763ApprovedInvestigational[A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis. … [L48186] Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells, leading to the release of cytokines and growth factors.
Synonyms: N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOANILINO)PYRIMIDIN-4-YL)BENZAMIDETranexamic acid
go.drugbank.com/drugs/DB00302ApprovedInvestigationalIt possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent.
Products: ZYEX-T, HEAMIC-T (Tranexamic Acid Injection 100mg/mL)Docetaxel
go.drugbank.com/drugs/DB01248ApprovedInvestigational[A259676] Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin. … [A259676,L46466] Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death.
Synonyms: N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol, N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxelCintredekin besudotox
go.drugbank.com/drugs/DB05305InvestigationalCintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, _Pseudomonas exotoxin_ (PE). The IL13 portion binds to receptors on the tumor. … Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual
Talazoparib
go.drugbank.com/drugs/DB11760ApprovedInvestigational[L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020.
Zosuquidar
go.drugbank.com/drugs/DB06191InvestigationalZosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with t...
Pholcodine
go.drugbank.com/drugs/DB09209ApprovedIllicitIt belongs to the opioid family of compounds and it is widely used. … [A31738] Pholcodine activity is the suppression of unproductive cough and it also has a mild sedative effect with little or no analgesic effects.